We are happy to share the great news!

An innovative study lead by Claudia Bagni was recently funded by Telethon to explore an mRNA-based therapy for Fragile X syndrome. This project will be developed between our Department (DNF, Lausanne) and the Department of Biomedicine and Prevention, University of Rome Tor Vergata and, in close collaboration with the Catholic University of Rome, the Italian Fragile X Association and Moderna Therapeutics.